Cardiovascular Toxicities of Androgen Deprivation Therapy.
Curr Treat Options Oncol
; 22(6): 47, 2021 04 17.
Статья
в английский
| MEDLINE | ID: covidwho-1188176
ABSTRACT
OPINION STATEMENT Prostate cancer is the second leading cause of cancer death in men, and cardiovascular disease is the number one cause of death in patients with prostate cancer. Androgen deprivation therapy, the cornerstone of prostate cancer treatment, has been associated with adverse cardiovascular events. Emerging data supports decreased cardiovascular risk of gonadotropin releasing hormone (GnRH) antagonists compared to agonists. Ongoing clinical trials are assessing the relative safety of different modalities of androgen deprivation therapy. Racial disparities in cardiovascular outcomes in prostate cancer patients are starting to be explored. An intriguing inquiry connects androgen deprivation therapy with reduced risk of COVID-19 infection susceptibility and severity. Recognition of the cardiotoxicity of androgen deprivation therapy and aggressive risk factor modification are crucial for optimal patient care.
ключевые слова
Полный текст:
Имеется в наличии
Коллекция:
Международные базы данных
база данных:
MEDLINE
Основная тема:
Prostatic Neoplasms
/
Cardiovascular Diseases
/
Antineoplastic Agents, Hormonal
Тип исследования:
Наблюдательное исследование
/
Прогностическое исследование
Пределы темы:
Люди
/
Мужчины
Язык:
английский
Журнал:
Curr Treat Options Oncol
Тематика журнала:
Онкология
Год:
2021
Тип:
Статья
Аффилированная страна:
S11864-021-00846-z
Документы, близкие по теме
MEDLINE
...
LILACS
LIS